🇺🇸 SALMETEROL XINAFOATE in United States

10,900 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthma — 2,539 reports (23.29%)
  2. Dyspnoea — 1,679 reports (15.4%)
  3. Drug Ineffective — 1,456 reports (13.36%)
  4. Cough — 940 reports (8.62%)
  5. Wheezing — 896 reports (8.22%)
  6. Headache — 791 reports (7.26%)
  7. Pneumonia — 673 reports (6.17%)
  8. Off Label Use — 651 reports (5.97%)
  9. Pain — 645 reports (5.92%)
  10. Therapeutic Product Effect Incomplete — 630 reports (5.78%)

Source database →

SALMETEROL XINAFOATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SALMETEROL XINAFOATE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for SALMETEROL XINAFOATE in United States?

Marketing authorisation holder not available in our data.